Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
60 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Traveler's Diarrhea - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Traveler's Diarrhea - Pipeline Review, H2 2014', provides an overview of the Traveler's Diarrhea's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Traveler's Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traveler's Diarrhea and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Traveler's Diarrhea - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Traveler's Diarrhea and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Traveler's Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Traveler's Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Traveler's Diarrhea - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Traveler's Diarrhea pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Traveler's Diarrhea Overview 7 Therapeutics Development 8 Pipeline Products for Traveler's Diarrhea - Overview 8 Pipeline Products for Traveler's Diarrhea - Comparative Analysis 9 Traveler's Diarrhea - Therapeutics under Development by Companies 10 Traveler's Diarrhea - Therapeutics under Investigation by Universities/Institutes 11 Traveler's Diarrhea - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Traveler's Diarrhea - Products under Development by Companies 15 Traveler's Diarrhea - Products under Investigation by Universities/Institutes 16 Traveler's Diarrhea - Companies Involved in Therapeutics Development 17 Chiesi Farmaceutici SpA 17 Cosmo Pharmaceuticals S.p.A 18 GlycoVaxyn AG 19 Nippon Shinyaku Co., Ltd. 20 Prokarium Ltd. 21 Scandinavian Biopharma Holding AB 22 Sigmoid Pharma Limited 23 Traveler's Diarrhea - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 ACE-527 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ACE-920 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Etvax - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 GVXNSD-133 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 helicobacter pylori vaccine [Hel-305] (multivalent) - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 INX-201 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 prulifloxacin - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 rifamycin - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Typhetec - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Traveler's Diarrhea - Recent Pipeline Updates 47 Traveler's Diarrhea - Discontinued Products 50 Traveler's Diarrhea - Product Development Milestones 51 Featured News & Press Releases 51 Oct 04, 2013: Santarus Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers' Diarrhea 51 Sep 11, 2012: Santarus Announces Positive Top-Line Phase III Results For Rifamycin SV MMX In Travelers' Diarrhea 52 Aug 17, 2011: TD Vaccines To Present ACE527 Phase II Data At Sachs 11th Annual Biotech In Europe 53 Sep 14, 2009: Data From Optimers Second Phase III Study of Prulifloxacin Presented At Annual Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC) 54 Sep 02, 2009: Optimer Pharmaceuticals Announces Presentations Of Additional Phase III Prulifloxacin Data At Upcoming ICAAC Annual Meeting 54 Feb 26, 2009: Optimer Pharmaceuticals Announces Publication In Peer-Reviewed Journal About Prulifloxacins Antibacterial Activity Against Infectious Diarrhea Producing Bacteria 55 Feb 24, 2009: Optimer Pharmaceuticals Announces Positive Results From Second Phase III Study Of Prulifloxacin For Infectious Diarrhea In Travelers 55 Oct 20, 2008: Data from Optimer Pharmaceuticals Prulifloxacin Phase III Trial In Travelers Diarrhea Presented At ICAAC/IDSA Annual Meeting 56 Sep 02, 2008: Optimer Pharmaceuticals Completes Enrollment In Second Prulifloxacin Phase III Clinical Trial 57 Jul 16, 2008: Optimer Pharmaceuticals Announces Positive Results In Prulifloxacin Phase III Study 57 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 60 Disclaimer 60
List of Tables Number of Products under Development for Traveler's Diarrhea, H2 2014 8 Number of Products under Development for Traveler's Diarrhea - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Number of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Late Stage Development, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Products under Investigation by Universities/Institutes, H2 2014 16 Traveler's Diarrhea - Pipeline by Chiesi Farmaceutici SpA, H2 2014 17 Traveler's Diarrhea - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2014 18 Traveler's Diarrhea - Pipeline by GlycoVaxyn AG, H2 2014 19 Traveler's Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014 20 Traveler's Diarrhea - Pipeline by Prokarium Ltd., H2 2014 21 Traveler's Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2014 22 Traveler's Diarrhea - Pipeline by Sigmoid Pharma Limited, H2 2014 23 Assessment by Monotherapy Products, H2 2014 24 Number of Products by Stage and Target, H2 2014 26 Number of Products by Stage and Mechanism of Action, H2 2014 28 Number of Products by Stage and Route of Administration, H2 2014 30 Number of Products by Stage and Molecule Type, H2 2014 32 Traveler's Diarrhea Therapeutics - Recent Pipeline Updates, H2 2014 47 Traveler's Diarrhea - Discontinued Products, H2 2014 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
